Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
FXYD5 encodes a member of a family of small membrane proteins that share a 35-amino acid signature sequence domain, beginning with the sequence PFXYD and containing 7 invariant and 6 highly conserved amino acids. Zusätzlich bieten wir Ihnen FXYD5 Proteine (7) und FXYD5 Kits (2) und viele weitere Produktgruppen zu diesem Protein an.
Showing 10 out of 63 products:
Human Polyclonal FXYD5 Primary Antibody für ELISA, IHC - ABIN249469
Tsuiji, Takasaki, Sakamoto, Irimura, Hirohashi: Aberrant O-glycosylation inhibits stable expression of dysadherin, a carcinoma-associated antigen, and facilitates cell-cell adhesion. in Glycobiology 2003
Show all 2 Pubmed References
Human Polyclonal FXYD5 Primary Antibody für WB - ABIN2776197
Miller, Davis: FXYD5 modulates Na+ absorption and is increased in cystic fibrosis airway epithelia. in American journal of physiology. Lung cellular and molecular physiology 2008
the ratio between FXYD5 and alpha1-beta1 heterodimer determines whether the Na,K-ATPase (zeige ATP1A1 Antikörper) acts as a positive or negative regulator of intercellular adhesion.
Knockdown of FXYD5 in MDA-MB-231 breast cancer cells largely decreases expression and secret (zeige IRF6 Antikörper)ion of the chemok (zeige CCL2 Antikörper)ine CCL2 (MCP-1). A related effect has also been observed in renal cell carcinoma cells.
Study demonstrated that the expression of FXYD1 (zeige FXYD1 Antikörper), FXYD3 (zeige FXYD3 Antikörper) and FXYD5 is elevated in the lungs of Acute respiratory distress syndrome patients
Dysadherin-silenced side population cells exhibited reduced expression of Bcl-2 (zeige BCL2 Antikörper) and Bax (zeige BAX Antikörper) compared with that prior to silencing.
we are focusing on the role of dysadherin in E-cadherin (zeige CDH1 Antikörper) downregulation, the various expression patterns of the molecule in head and neck cancer
Findings suggest that dysadherin might contribute to breast cancer progression through AKT (zeige AKT1 Antikörper) activation.
These results suggest a role of let-7a down-regulation in the development of thyroid neoplasias of the follicular histotype, likely regulating dysadherin protein expression levels.
Data show that osteoblasts are the major cell type of the bone marrow that affect RCC (zeige XRCC1 Antikörper) cells by secreting factors that increase the expression of dysadherin and CCL2 (zeige CCL2 Antikörper) in the tumor cells leading to enhanced cell migration.
This is the first report on expression of dysadherin in the male gonad and in spermatozoa.
Overexpression of Snail (zeige SNAI1 Antikörper), Slug, and dysadherin and activation of Wnt (zeige WNT2 Antikörper) and PI3K (zeige PIK3CA Antikörper)/Akt (zeige AKT1 Antikörper) signaling was associated with inactivated E-cadherin (zeige CDH1 Antikörper) in the spindle cells of monophasic fibrous synovial sarcomas.
FXYD5 mediates metastatic progression through regulation of the beta Na(+)-K(+)-ATPase (zeige ATP1A1 Antikörper) subunit in the 4T1 mouse breast cancer model.
transfection of M1 epithelial cell line with FXYD5 largely increases lipopolysaccharide (LPS (zeige TLR4 Antikörper)) stimulated CCL2 (zeige CCL2 Antikörper) mRNA and secretion of the translated protein
FXYD5 affects cell polarization through its interaction with Na(+)-K(+)-ATPase (zeige ATP1A1 Antikörper).
Expressing FXYD5 in mouse kidney collecting duct cell line M1 led to a large decrease in amiloride-insensitive transepithelial electrical resistance as well as increased permeability to 4-kDa dextran.
The role of FXYD5 in Na,K-ATPase (zeige ATP1A1 Antikörper) activity, its cellular and tissue distribution, and its biochemical properties are reported.
data suggest that different FXYD proteins interact similarly with the Na(+)-K(+)-ATPase (zeige ATP1A1 Antikörper) and their transmembrane domains
FXYD5 is significantly increased in the lungs and nasal epithelium of cystic fibrosis (zeige S100A8 Antikörper) mice as assessed by RT-PCR.
This gene encodes a member of a family of small membrane proteins that share a 35-amino acid signature sequence domain, beginning with the sequence PFXYD and containing 7 invariant and 6 highly conserved amino acids. The approved human gene nomenclature for the family is FXYD-domain containing ion transport regulator. Mouse FXYD5 has been termed RIC (Related to Ion Channel). FXYD2, also known as the gamma subunit of the Na,K-ATPase, regulates the properties of that enzyme. FXYD1 (phospholemman), FXYD2 (gamma), FXYD3 (MAT-8), FXYD4 (CHIF), and FXYD5 (RIC) have been shown to induce channel activity in experimental expression systems. Transmembrane topology has been established for two family members (FXYD1 and FXYD2), with the N-terminus extracellular and the C-terminus on the cytoplasmic side of the membrane. This gene product, FXYD5, is a glycoprotein that functions in the up-regulation of chemokine production, and it is involved in the reduction of cell adhesion via its ability to down-regulate E-cadherin. It also promotes metastasis, and has been linked to a variety of cancers. Alternative splicing results in multiple transcript variants.
FXYD domain-containing ion transport regulator 5
, FXYD domain containing ion transport regulator 5
, keratinocytes associated transmembrane protein 1
, ion channel homolog RIC
, oncoprotein induced transcript 2
, oncoprotein-induced protein 2